Biovail Receives Canadian Approval For Ralivia™ For The Treatment Of Moderately Severe Pain Biovail Corporation (NYSE:BVF)(TSX:BVF) announced that it has received an expanded indication for once-daily Ralivia™ - to include the treatment of moderately severe pain in addition to moderate pain - from the Therapeutic Products Directorate (TPD) in Canada. Ralivia™ is now indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more.
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 AM
